Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
Subscribe To Our Newsletter & Stay Updated
